



OPEN

Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, Mulugeta Seneshaw, Divya P. Kumar, Hae-Ki Min, Prasanna K. Santhekadur, Bubu Banini, Adolfo Gabriele Mauro, Abdul M. Oseini, Robert Vincent, Keith O. Tanis, Andrea L. Webber, Liangsu Wang, Pierre Bedossa, Faridoddin Mirshahi & Arun J. Sanyal

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-17370-6>, published online 08 December 2017

In this Article, the authors neglected to include some potential conflict of interest. The Competing Interest section should read:

Competing interests

Dr. Sanyal is the founder of the company Sanyal Biotechnology that performs pre-clinical drug-testing using the DIAMOND model. Virginia Commonwealth University has ownership interests in Sanyal Bio.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020